

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YSB Inc.**

**藥師幫股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9885)**

## **VOLUNTARY ANNOUNCEMENT ENTRY INTO INVESTMENT AGREEMENT**

This announcement is made by YSB Inc. (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that, on 28 February 2024, Guangzhou Yaobang Information Technology Co., Ltd. (廣州藥幫信息科技有限公司) (“**Guangzhou Yaobang**”), a subsidiary of the Company, has entered into an investment agreement with Shanghai Ruize Youan Health Technology Co., Ltd. (上海睿擇佑安健康科技有限公司) (“**Ruize Health**”) and its shareholders (the “**Investment Agreement**”). Pursuant to the Investment Agreement, Guangzhou Yaobang will hold a 13% equity interest in Ruize Health for the consideration of RMB10.0 million, subject to certain conditions specified in the Investment Agreement. After completion, the Company anticipates Ruize Health to become an important business partner for the Group.

The target company Ruize Health is a third-party service company that focuses on “healthcare consumption + commercial insurance”. Its primary business includes the provision of product design and risk control, health claims review and other supporting services to cooperative insurance institutions by connecting healthcare supply chain, insurance companies and consumers in a joint bid to create commercial insurance products covering consumers’ daily healthcare consumption and to support the building and improvement of a multi-layered medical insurance system. The commercial insurance as a new payer introduced by Ruize Health will assist healthcare supply chain-related enterprises including pharmaceutical businesses and distribution companies in achieving more precise contact with consumers and providing them with services through commercial insurance-designated pharmacies and commercial insurance drug catalogues.

To the best knowledge and information of the Board, having made all reasonable enquiries, as at the date of this announcement, the other parties to the Investment Agreement (including Ruize Health) and their ultimate beneficial owners, where applicable, are independents third parties and not connected persons of the Company.

Our Company adheres to the mission of “To make quality medical care and good medicine accessible to all” (讓好醫好藥普惠可及), and strives to continuously promote fairness and accessibility of medicine to downstream customers. We believe that Ruize Health and its business align with this mission and this investment will help us explore new service models to make medicine more accessible for all, through providing commercial insurance, enabling consumers greater access to secure medicine and medical services, and expanding the downstream demand of our customers. Additionally, this investment will help expand the Group’s ability to empower upstream industrial production and sales through more accurate terminal consumption/demand data. Therefore, this investment will assist in building a comprehensive ecosystem for various players in the healthcare and pharmaceutical space. Accordingly, we believe that this investment will be beneficial for improving our overall business performance and range and is in line with the overall long-term development plan of our Group.

As all the applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on the Stock Exchange, the “**Listing Rules**”) in respect of such investment (and Investment Agreement) are less than 5%, and none of the other parties to the Investment Agreement is a connected person of the Company, the investment (and Investment Agreement) does not constitute a notifiable or connected transaction under the Listing Rules. Accordingly, this announcement is made by the Company on a voluntary basis.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**YSB Inc.**  
**Mr. Buzhen Zhang**  
*Chairman and executive Director*

Hong Kong, 28 February 2024

*As of the date of this announcement, the Board comprises Mr. Buzhen Zhang and Mr. Fei Chen as executive directors, and Mr. Ziyang Zhu as the non-executive director, and Ms. Rong Shao, Mr. Sam Hanhui Sun and Mr. Hongqiang Zhao as independent non-executive directors.*